Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI-1206 plus pembrolizumab in advanced solid tumors
2023-509846-36-00Phase 2Authorised
- Sponsor
- BioInvent International
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of BI-1206 and pembrolizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and intraocular melanoma (4 arms), sponsored by BioInvent International. Primary endpoints: Safety and tolerability, Dose-limiting toxicity and dose finding and 1 more. Planned start May 2020; status: authorised.
02
Drugs
BI-1206pembrolizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)intraocular melanoma
Beyond the preview
Go deeper on 2023-509846-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509846-36-00.